Target intelligence / Profile preview

Vesicular glutamate transporter 2 (VGLUT2)

Target
VGLUT2
Molecular classification
Transporter, Solute carrier family, Organic anion transporter, Synaptic vesicle protein
01

Overview

Vesicular glutamate transporter 2 (VGLUT2) is a membrane protein belonging to the solute carrier family 17, encoded by the SLC17A6 gene. It is primarily expressed in neuronal synaptic vesicles where it mediates the storage of glutamate, the major excitatory neurotransmitter, by transporting cytosolic glutamate into vesicles in preparation for synaptic release. VGLUT2 relies on the membrane potential (ΔΨ) and requires allosteric activation by protons (H⁺) and chloride ions (Cl⁻). It also exhibits a Cl⁻-conductance mechanism and, in certain contexts, can mediate Na⁺-dependent inorganic phosphate uptake, although its primary function is related to glutamate transport. Dysfunction or altered regulation of VGLUT2 is implicated in numerous CNS disorders characterized by abnormal excitatory neurotransmission, including epilepsy, schizophrenia, neurodegenerative diseases, and pain syndromes.

Other names
SLC17A6VGLUT2VGluT2DNPIVesicular glutamate transporter 2Differentiation-associated BNPIDifferentiation-associated Na(+)-dependent inorganic phosphate cotransporterSolute carrier family 17 member 6BNPI
02

Mechanism of action

For inhibitors: Block VGLUT2-mediated vesicular glutamate uptake, decreasing synaptic glutamate release and excitatory neurotransmission

03

Biological functions

Glutamate transport into synaptic vesicles (vesicular neurotransmitter loading)Regulation of excitatory neurotransmissionPhosphate ion homeostasisAssociated ion conductance (Cl⁻, Na⁺, K⁺, H⁺)
04

Disease associations

Neurodegenerative disease (altered glutamate handling implicated in ALS, Huntington's, Alzheimer's)Epilepsy (excitatory/inhibitory imbalance)SchizophreniaNeurodevelopmental disordersPain disorders (chronic pain via glutamatergic pathways)Potential role in psychiatric conditions
05

Safety considerations

Inhibition may cause widespread CNS effects including impaired synaptic transmissionNeurotoxicity due to glutamate dysregulationGlobal reduction of excitatory signaling
06

Interacting drugs

No approved drugs directly target VGLUT2 clinically as of 2024.

2 more in the full profile.

07

Biomarkers

Increased or altered expression in specific brain regions can be used as a biomarker for excitatory neuron populations or disease states

Beyond the preview

Go deeper on Vesicular glutamate transporter 2 (VGLUT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vesicular glutamate transporter 2 (VGLUT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call